Viatris completes Pacira acquisition
Viatris closed its cash tender offer and merger for Pacira, which becomes a wholly owned subsidiary and will be delisted from Nasdaq
Key takeaways
- Viatris completed its acquisition of Pacira BioSciences on Nov. 17, 2026, paying $36.50 per Share in cash.
- Approximately 32,929,780 Shares, about 66.46% of outstanding Shares, were tendered before the merger closed.
- Viatris expects Pacira to contribute total revenues of between $90 million and $100 million for the remainder of 2026.
Viatris said on Nov. 17, 2026 that it completed the Viatris deal to acquire Pacira BioSciences, Inc. (PCRX). The transaction was first announced on Oct. 8, 2026.
According to the release, the tender offer paid $36.50 per Share in cash, net of applicable withholding taxes and without interest. It expired one minute after 11:59 p.m., Eastern Time, on Nov. 16, 2026.
Viatris deal: the details
Equiniti Trust Company, LLC, the depositary, told Viatris that holders validly tendered and did not validly withdraw approximately 32,929,780 Shares. That represented approximately 66.46% of the total outstanding Shares as of the Expiration Time. All conditions to the tender offer stood satisfied or waived on Nov. 17, 2026. Peach Purchaser Sub Inc., a wholly owned Viatris subsidiary, then accepted those Shares for payment.
Viatris said Purchaser then merged with and into Pacira under Section 251(h) of the General Corporation Law of the State of Delaware, without a vote of Pacira’s stockholders. Pacira continues as the surviving corporation and a wholly owned subsidiary of Viatris. Viatris acquired the Shares not tendered, and each now carries the right to receive the Offer Price. Completion of the transaction will result in Pacira’s delisting from the Nasdaq Global Select Market.
| Consideration (cash / stock / assumed debt) | $36.50 per Share in cash, net of applicable withholding taxes and without interest |
|---|---|
| What is acquired or divested | All issued and outstanding common stock of Pacira BioSciences, Inc. (PCRX) |
| Ownership change (share count, stake %) | Approximately 32,929,780 Shares tendered, approximately 66.46% of outstanding Shares; Pacira is now a wholly owned subsidiary of Viatris |
| Guidance after close | Total revenues of between $90 million and $100 million from November 17, 2026, through December 31, 2026 |
| Closing conditions and timing | All conditions satisfied or waived on Nov. 17, 2026; merger completed under Section 251(h) without a Pacira stockholder vote |
- “Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business,” said Scott A. Smith, CEO of Viatris.
- “With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management.”
Background to the Viatris deal
Viatris describes itself as a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. Its portfolio spans generics, value-added medicines, established brands and innovative medicines. The company has its headquarters in the US, with global centers in Pittsburgh, Shanghai and Hyderabad, India. It trades on Nasdaq under VTRS.
The news moving money, markets, and the world—before your day starts.
Daily. Free. Join 34,000+ readers across crypto, finance, and policy.
What this means
For VTRS holders, the release says the acquisition adds Pacira to Viatris’ US innovative medicines business, with a revenue contribution stated only for the rest of 2026. The release also lists the possibility that Viatris may not realize the anticipated benefits, synergies and operating efficiencies of the Pacira acquisition as a risk.
Analysis
The closing turns Pacira from a listed peer into a wholly owned Viatris subsidiary, giving Viatris the non-opioid pain management position its CEO tied to strengthening the US innovative medicines business. The $90 million to $100 million revenue range covers only November 17, 2026, through December 31, 2026, so the deal’s full-year contribution is still open.
Viatris’ own risk factors name the possibility of not realizing the anticipated benefits, synergies and operating efficiencies of the acquisition. Integration results are likely to become clearer in later reporting, which may show whether the deal accelerates the sustained revenue and earnings growth management described.
What to watch
- 2026-11-23: VTRS goes ex-dividend: $0.12 a share, paid 16 Dec. It is the first dividend date for Viatris after closing the Pacira acquisition.
- Delisting of Pacira Shares from the Nasdaq Global Select Market. It completes the removal of PCRX as a separate listed company under Viatris.
- Viatris reporting of Pacira revenue for the period through December 31, 2026. It will show results against the $90 million to $100 million range Viatris stated.
The crypto angle
- Viatris Inc has 2 tokenized versions across 11 known blockchains: Arbitrum One, BNB Smart Chain, Ethereum, HyperEVM, Ink, Mantle, Morph L2, Optimism, Solana, TON, and X Layer.
More market coverage: Crypto Briefing Markets
Source: Viatris, 2026-11-17 13:50 UTC
Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.

